CymaBay Therapeutics Inc (CBAY) stock has fallen -48.98% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CBAY stock a score of 32 out of a possible 100. That rank is mainly influenced by a short-term technical score of 1. CBAY's rank also includes a long-term technical score of 13. The fundamental score for CBAY is 81. In addition to the average rating from Wall Street analysts, CBAY stock has a mean target price of $11.50. This means analysts expect the stock to increase 187.50% over the next 12 months.
CymaBay Therapeutics Inc (CBAY) Stock Loses -7.41% This Week; Should You Buy?
CBAY has an Overall Score of 32. Find out what this means to you and get the rest of the rankings on CBAY!